{"doi":"10.1007/s00401-020-02157-3","title":"The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies","abstract":"<jats:title>Abstract</jats:title><jats:p>Synucleinopathies, such as Parkinson’s disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB), are defined by the presence of α-synuclein (αSYN) aggregates throughout the nervous system but diverge from one another with regard to their clinical and pathological phenotype. The recent generation of pure fibrillar αSYN polymorphs with noticeable differences in structural and phenotypic traits has led to the hypothesis that different αSYN strains may be in part responsible for the heterogeneous nature of synucleinopathies. To further characterize distinct αSYN strains in the human brain, and establish a structure-pathology relationship, we pursued a detailed comparison of αSYN assemblies derived from well-stratified patients with distinct synucleinopathies. We exploited the capacity of αSYN aggregates found in the brain of patients suffering from PD, MSA or DLB to seed and template monomeric human αSYN in vitro via a protein misfolding cyclic amplification assay. A careful comparison of the properties of total brain homogenates and pure in vitro amplified αSYN fibrillar assemblies upon inoculation in cells and in the rat brain demonstrates that the intrinsic structure of αSYN fibrils dictates synucleinopathies characteristics. We report that MSA strains show several similarities with PD strains, but are significantly more potent in inducing motor deficits, nigrostriatal neurodegeneration, αSYN pathology, spreading, and inflammation, reflecting the aggressive nature of this disease. In contrast, DLB strains display no or only very modest neuropathological features under our experimental conditions. Collectively, our data demonstrate a specific signature for PD, MSA, and DLB-derived strains that differs from previously described recombinant strains, with MSA strains provoking the most aggressive phenotype and more similarities with PD compared to DLB strains.</jats:p>","journal":"Acta Neuropathologica","year":2020,"id":604530,"datarank":6.965791990974602,"base_score":5.69035945432406,"endowment":5.69035945432406,"self_citation_contribution":0.8535539181486091,"citation_network_contribution":6.112238072825993,"self_endowment_contribution":0.8535539181486091,"citer_contribution":6.112238072825993,"corpus_percentile":null,"corpus_rank":null,"citation_count":295,"citer_count":200,"citers_with_citation_signal":197,"citers_with_endowment":197,"datacite_reuse_total":25,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":232825,"name":"Géraldine Gelders","orcid":"0000-0003-4471-0365","position":1,"is_corresponding":false},{"id":890582,"name":"Alexis Fenyi","orcid":"0000-0003-3270-2085","position":2,"is_corresponding":false},{"id":1551097,"name":"Luc Bousset","orcid":null,"position":3,"is_corresponding":false},{"id":1551098,"name":"Filipa Brito","orcid":null,"position":4,"is_corresponding":false},{"id":703563,"name":"Wouter Peelaerts","orcid":"0000-0003-3776-4162","position":5,"is_corresponding":false},{"id":232820,"name":"Chris Van den Haute","orcid":"0000-0002-6650-3845","position":6,"is_corresponding":false},{"id":561215,"name":"Steve Gentleman","orcid":null,"position":7,"is_corresponding":false},{"id":625538,"name":"Ronald Melki","orcid":"0000-0003-0000-7096","position":8,"is_corresponding":false},{"id":232830,"name":"Veerle Baekelandt","orcid":"0000-0001-8966-2921","position":9,"is_corresponding":false},{"id":1551095,"name":"Anke Van der Perren","orcid":"0000-0003-2924-7392","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies","abstract":"<jats:title>Abstract</jats:title><jats:p>Synucleinopathies, such as Parkinson’s disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB), are defined by the presence of α-synuclein (αSYN) aggregates throughout the nervous system but diverge from one another with regard to their clinical and pathological phenotype. The recent generation of pure fibrillar αSYN polymorphs with noticeable differences in structural and phenotypic traits has led to the hypothesis that different αSYN strains may be in part responsible for the heterogeneous nature of synucleinopathies. To further characterize distinct αSYN strains in the human brain, and establish a structure-pathology relationship, we pursued a detailed comparison of αSYN assemblies derived from well-stratified patients with distinct synucleinopathies. We exploited the capacity of αSYN aggregates found in the brain of patients suffering from PD, MSA or DLB to seed and template monomeric human αSYN in vitro via a protein misfolding cyclic amplification assay. A careful comparison of the properties of total brain homogenates and pure in vitro amplified αSYN fibrillar assemblies upon inoculation in cells and in the rat brain demonstrates that the intrinsic structure of αSYN fibrils dictates synucleinopathies characteristics. We report that MSA strains show several similarities with PD strains, but are significantly more potent in inducing motor deficits, nigrostriatal neurodegeneration, αSYN pathology, spreading, and inflammation, reflecting the aggressive nature of this disease. In contrast, DLB strains display no or only very modest neuropathological features under our experimental conditions. Collectively, our data demonstrate a specific signature for PD, MSA, and DLB-derived strains that differs from previously described recombinant strains, with MSA strains provoking the most aggressive phenotype and more similarities with PD compared to DLB strains.</jats:p>","is_dataset_classified":null,"base_score":5.69035945432406,"endowment":5.69035945432406,"datacite_reuse_total":25,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32356200","pmcid":"PMC7244622","openalex_id":"https://openalex.org/W3021415691","authors":[],"funders":[{"funder_name":"Fonds Wetenschappelijk Onderzoek","grant_id":"G.0927.14","title":null},{"funder_name":"Fonds Wetenschappelijk Onderzoek","grant_id":"G080517N","title":null},{"funder_name":"Fonds Wetenschappelijk Onderzoek","grant_id":"12K0216N","title":null},{"funder_name":"JPND","grant_id":"SYNACTION-ANR-15-JPWG-0012-03","title":null},{"funder_name":"Fondation Recherche Médicale","grant_id":"20160334896","title":null},{"funder_name":"EC Joint Programme on Neurodegenerative Diseases TransPathND","grant_id":"ANR-17-JPCD-0002-02","title":null},{"funder_name":"EFPIA Innovative Medicines Initiative 2","grant_id":"IMPRiND grant agreement No 116060","title":null},{"funder_name":"King Baudouin Foundation","grant_id":"Fund Sophia","title":null},{"funder_name":"Parkinson's UK","grant_id":"J-1402","title":null},{"funder_name":"European Commission","grant_id":"116060","title":"Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060"},{"funder_name":"French National Research Agency (ANR)","grant_id":"ANR-17-JPCD-0002","title":"Intraneuronal transport-related pathways across neurodegenerative diseases"},{"funder_name":"French National Research Agency (ANR)","grant_id":"ANR-15-JPWG-0012","title":"Unravelling the pathophysiological role of alpha-synuclein aggregation, transmission and neuroinflammation in neurodegeneration"},{"funder_name":"European Commission","grant_id":"643417","title":"ERA-NET for establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020"},{"funder_name":"Fondation Bettencourt-Schueller","grant_id":"","title":null},{"funder_name":"Centre National de la Recherche Scientifique","grant_id":"","title":null},{"funder_name":"Flemish Parkinson Liga","grant_id":"","title":null},{"funder_name":"Medical Foundation Queen Elisabeth","grant_id":"","title":null},{"funder_name":"Fondation Simone et Cino Del Duca","grant_id":"","title":null}],"total_grants":18,"fwci":13.9756,"citation_percentile":0.99206459,"influential_citations":0,"citation_trend":[{"year":2019,"count":1},{"year":2020,"count":10},{"year":2021,"count":58},{"year":2022,"count":51},{"year":2023,"count":48},{"year":2024,"count":63},{"year":2025,"count":44},{"year":2026,"count":20}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007/s00401-020-02157-3.pdf","host_type":"journal"},{"url":"https://link.springer.com/content/pdf/10.1007/s00401-020-02157-3.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s00401-020-02157-3/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1007/s00401-020-02157-3","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/32356200","host_type":"repository"},{"url":"https://lirias.kuleuven.be/handle/123456789/667662","host_type":"repository"},{"url":"https://cea.hal.science/cea-02561795","host_type":"repository"},{"url":"https://lirias.kuleuven.be/bitstream/123456789/656722/2/The%20structural%20differences%20between%20patient-derived%20%ce%b1-synuclein%20strains%20dictate%20characteristics%20of%20Parkinsons%20disease%2c%20multip.pdf","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7244622","host_type":"repository"},{"url":"http://hdl.handle.net/10044/1/80075","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC7244622","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7244622?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.1007/s00401-020-02157-3","host_type":""},{"url":"https://dx.doi.org/10.1007/s00401-020-02157-3","host_type":""},{"url":"https://cea.hal.science/cea-02561795v1/document","host_type":""},{"url":"https://cea.hal.science/cea-02561795v1","host_type":""},{"url":"https://doi.org/https://doi.org/10.1007/s00401-020-02157-3","host_type":""}],"fields_of_study":["Parkinson's Disease Mechanisms and Treatments","Neurological disorders and treatments","Ginkgo biloba and Cashew Applications","0301 basic medicine","03 medical and health sciences","0303 health sciences","Aged","Aged, 80 and over","Brain","Dementia","Female","Humans","Lewy Body Disease","Male","Middle Aged","Multiple System Atrophy","Parkinson Disease","alpha-Synuclein"],"mesh_terms":["Aged","Aged, 80 and over","Brain","Dementia","Female","Humans","Male","Middle Aged","Parkinson Disease","Multiple System Atrophy","Lewy Body Disease","alpha-Synuclein"],"keywords":["Dementia with Lewy bodies","Parkinson's disease","Atrophy","Dementia","Lewy body","Medicine","Disease","Alpha-synuclein","Pathology","Degenerative disease","Neuroscience","Psychology","Strains","α-synuclein","Neurodegenerative Disorders","Synucleinopathies","Lewy Body Disease","Male","570","TRANSMISSION","ASSEMBLIES","Clinical Neurology","610","DIAGNOSIS","OLIGOMERS","RAT MODEL","Humans","[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]","[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM]","Aged","Aged, 80 and over","Original Paper","Science & Technology","Neurology & Neurosurgery","[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology","Neurosciences","NEURODEGENERATION","Brain","1103 Clinical Sciences","Parkinson Disease","AGGREGATION","Middle Aged","Multiple System Atrophy","INCLUSIONS","[SDV] Life Sciences [q-bio]","3209 Neurosciences","Female","Neurosciences & Neurology","OVEREXPRESSION","1109 Neurosciences","Life Sciences & Biomedicine"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":13,"sdg_label":"13. Climate action"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.14813704.v1","title":"Additional file 1 of Differential seeding and propagating efficiency of α-synuclein strains generated in different conditions","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.14813704","title":"Additional file 1 of Differential seeding and propagating efficiency of α-synuclein strains generated in different conditions","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16944567.v1","title":"Additional file 1 of High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16944567","title":"Additional file 1 of High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20130877.v1","title":"Additional file 1 of Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20130877","title":"Additional file 1 of Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20967836.v1","title":"Additional file 1 of Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20967836","title":"Additional file 1 of Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.25902365.v1","title":"Additional file 1 of A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.25902365","title":"Additional file 1 of A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.25902428.v1","title":"Additional file 2 of A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.25902428","title":"Additional file 2 of A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26586450.v1","title":"Additional file 1 of The G51D SNCA mutation generates a slowly progressive α-synuclein strain in early-onset Parkinson’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26586450","title":"Additional file 1 of The G51D SNCA mutation generates a slowly progressive α-synuclein strain in early-onset Parkinson’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26683984.v1","title":"Additional file 1 of Parkinson’s disease-derived α-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26683984","title":"Additional file 1 of Parkinson’s disease-derived α-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26725514.v1","title":"Additional file 3 of A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26725514","title":"Additional file 3 of A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26725517.v1","title":"Additional file 4 of A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26725517","title":"Additional file 4 of A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26725520.v1","title":"Additional file 5 of A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26725520","title":"Additional file 5 of A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26731756.v1","title":"Additional file 1 of A multiverse of α-synuclein: investigation of prion strain properties with carboxyl-terminal truncation specific antibodies in animal models","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26731756","title":"Additional file 1 of A multiverse of α-synuclein: investigation of prion strain properties with carboxyl-terminal truncation specific antibodies in animal models","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.17079427","title":"Additional file 7 of Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro","publisher":"figshare","resource_type":"Image"}],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T00:21:03.469878Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}